Literature DB >> 23953550

Outcome of TiNi stent treatments in symptomatic central airway stenoses caused by Aspergillus fumigatus infections after lung transplantation.

B X Xie1, Y M Zhu, C Chen, D P Zhao, C L Yang, J A Ding, G N Jiang.   

Abstract

BACKGROUND: Central airway stenoses due to Aspergillus fumigatus infections have been a significant cause of morbidity and mortality after lung transplantation. We reviewed our experience using self-expandable braided TiNi-metallic stents in the management of 4 single-lung transplant recipients with central airways stenoses between January 2003 and June 2010.
METHODS: Thirty-six single-lung transplant recipients were subjected to pulmonary function testing and surveillance bronchoscopy with biopsy at predetermined intervals and when clinically indicated. Bronchial wash fluid and biopsy material were examined by appropriate fungal stain and culture techniques.
RESULTS: Nine of 36 patients (25%) were diagnosed with Aspergillus fumigatus infections; 4 (11.1%) showed rapid decrease in pulmonary function and developed severe upper airway narrowings with about 80% of the central airway obstructed by thick plugs of mucus, heavily laden with Aspergillus species. All 4 patients were managed with stent placement as well as antifungal treatments and showed a forced vital capacity and forced expiratory volume in 1 second improvement of 11.3% and 25.9%, respectively after 1 month.
CONCLUSIONS: TiNi stent applications in combination with antifungal drugs are sufficient to treat central airway stenoses after lung transplantation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23953550     DOI: 10.1016/j.transproceed.2013.02.129

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Complex multimodality central airway management of aspergillus pseudomembranous tracheobronchitis.

Authors:  Samjot Singh Dhillon; Marwan Saoud; Kassem Harris
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.